When was Sana Biotechnology founded?

Sana Biotechnology was founded in 2018 and raised its 1st funding round 2 years after it was founded.

Where is Sana Biotechnology located?

Sana Biotechnology is headquartered in Seattle, United States. It is registered at Seattle, Washington.

Who is the current CEO of Sana Biotechnology?

Steve Harr of Sana Biotechnology. They have also founded 1 company.

How many employees does Sana Biotechnology have?

As of Jun 30, 2026, the latest employee count at Sana Biotechnology is 258.

Is Sana Biotechnology a funded company?

Sana Biotechnology is a funded company, having raised a total of $821M across 2 funding rounds to date. The company's 1st funding round was a $821M Series D round, raised on Jun 25, 2020.

When was the latest funding round of Sana Biotechnology?

Sana Biotechnology's latest funding was a $25M Post IPO round on Aug 10, 2026, with participation from 1 investor.

Is Sana Biotechnology a Oncology company?

The primary sectors of Sana Biotechnology are Oncology, Diabetes, Cell Therapy and Immunology.

Where does Sana Biotechnology rank among its competitors?

Sana Biotechnology ranks 3rd amongst 3664 active competitors, of which 1255 are funded. It stands 2nd in terms of total funding among its competitors. The most recent competitor to raise funding was Immuneel, which secured $10.5M in Jun, 2026.

Who are the top competitors of Sana Biotechnology?

Sana Biotechnology's top competitors include Jazz Pharmaceuticals, BeiGene and Ideaya Biosciences. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

Sana Biotechnology - 2026 Company Profile, Team, Funding, Competitors & Financials

Sana Biotechnology is a public company based in Seattle (United States), founded in 2018 by Geoffrey Von Maltzahn, Steve Harr and Jack Milwid. It operates as a Developer of engineered cell therapies for treating various human diseases. Sana Biotechnology has raised $821M in funding from investors like Google Ventures, Bezos Expeditions and Arch Venture Partners. The company has 3664 active competitors, including 1255 funded and 847 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Ideaya Biosciences.

Sectors and market segments that Sana Biotechnology operate in

Sana Biotechnology serves in the Life Sciences market segments.The primary business model of Sana Biotechnology are:

Company Details

Developer of engineered cell therapies for treating various human diseases. Research focuses on repairing or controlling genes within cells and replacing damaged or missing cells to address underlying disease causes. Drug candidates target conditions including diabetes, cancers, and autoimmune disorders. The work involves cellular biology and machine learning to create therapeutic interventions.

Website: sana.com
Social
Email ID: *****@sana.com
Registered Address: Seattle, Washington

Key Metrics

Founded Year

2018

Location

Seattle, United States

Stage

Public

Total Funding

$821M in 2 rounds

Latest Funding Round

Post IPO, Aug 10, 2026, $25M

Investors

Google Ventures & 18 more

Ranked

3^rd among 3664 active competitors

Employee Count

258 as on Jun 30, 2026

Investment & Acquisitions

Rippl Care & 2 more

Similar Companies

Jazz Pharmaceuticals & 3677 more

Exit Details

Public

View Sana Biotechnology's full profile

Sana Biotechnology is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Sana Biotechnology, Inc. CIN: 831381173 , United States, Active	Dec 26, 999	-	198 (As on Dec 31, 2024)	-

Sana Biotechnology got listed on Feb 04, 2021.

Click here to take a look at Sana Biotechnology's IPO in detail

Sana Biotechnology has raised a total funding of $821M over 2 rounds. Its first funding round was on Jun 25, 2020. Its latest funding round was a Post IPO round on Aug 10, 2026 for $25M. 1 investor participated in its latest round. Sana Biotechnology has 19 institutional investors.

Here is the list of recent funding rounds of Sana Biotechnology:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Aug 10, 2026	$25M	Post IPO	-	-	-	Mayo Clinic
Jun 25, 2020	$821M	Series D	-	-	F-Prime Capital, Arch Venture Partners, Flagship Pioneering, CPP Investments, Baillie Gifford, PSP Investments, Bezos Expeditions, Alaska Permanent Fund, Google Ventures, Omega Funds, Altitude Life Science Ventures	-

Access funding benchmarks and valuations. Sign up today!

View details of Sana Biotechnology's funding rounds and investors

The founders of Sana Biotechnology are Geoffrey Von Maltzahn, Steve Harr and Jack Milwid. Steve Harr is the CEO of Sana Biotechnology.

Here are the details of Sana Biotechnology's key team members:

Geoffrey Von Maltzahn: Co-Founder of Sana Biotechnology and founder of 6 other companies, including Quotient, Tessera Therapeutics and Indigo.
Contact Info: 1 email address
Steve Harr: Co-Founder & CEO of Sana Biotechnology.
Jack Milwid: Former Co-Founder of Sana Biotechnology and founder of 1 other company.

View details of Sana Biotechnology's Founder profiles and Board Members

Sana Biotechnology's employee count trend

Sana Biotechnology has 258 employees as of Jun 26. Here is Sana Biotechnology's employee count trend over the years:

Employee count trend for Sana Biotechnology

Uncover Sana Biotechnology's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Sana Biotechnology include Jazz Pharmaceuticals, BeiGene and Ideaya Biosciences. Here is the list of Top 10 competitors of Sana Biotechnology, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, Boxer Capital & 13 others	80/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	HTIF, Baillie Gifford & 17 others	73/100
4th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
5th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, New Enterprise Associates ... & 30 others	72/100
6th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
7th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Domain Associates, Fidelity Investments & 19 others	72/100
8th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	71/100
9th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	71/100
10th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on Sana Biotechnology's competitors? Click here to see the top ones

Sana Biotechnology has made 2 investments in Rippl Care and Beam Therapeutics and acquired Oscine Therapeutics.

Here is the list of these investments and acquisitions:

Date of Investment/Acquisition	Type	Company Name	Founded Year	Location
Sep 28, 2022	Investments	Rippl Care	2021	Seattle (United States)
Oct 19, 2021	Investments	Beam Therapeutics	2017	Cambridge (United States)
Nov 02, 2020	Acquisition	Oscine Therapeutics	2017	New York City (United States)